| Followers | 0 |
| Posts | 48 |
| Boards Moderated | 0 |
| Alias Born | 06/06/2022 |
Sunday, March 19, 2023 7:45:32 PM
If there was a back and forth between the fda and revive we would know what endpoint we should have chose. So this belief that there was communication is bs. Just stop with that. You are embarrassing yourself.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
